Drugs / ST1535
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05070702 | Nov 2021 → Jul 2022 | — | Circadian Therapeutics Ltd | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ST1535 | ChEMBL registry synonym — accepted as the source's own label CHEMBL197669 ↗ |
| Known as | CT-1500 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05070702 ↗ |
| Action | Inhibit | “Adenosine A2a receptor antagonist” CHEMBL197669 ↗ |
| Modality | Small molecule | — CHEMBL197669 ↗ |
| Route | Oral | “orally administered CT-1500” NCT05070702 ↗ |
| Target | ADORA2A | “Adenosine A2a receptor antagonist” CHEMBL197669 ↗ |